Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
D07AC03,D07XC02
CAS registry number (Chemical Abstracts Service)
0000382-67-2
Chemical Formula
C22-H29-F-O4
Molecular Weight
376
Therapeutic Categories
Dermatological agent
Adrenal cortex hormone, glucocorticoid
Chemical Name
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-, (11ß,16α)-
Foreign Names
- Desoximetasonum (Latin)
- Desoximetason (German)
- Désoximétasone (French)
- Desoximetasona (Spanish)
Generic Names
- Desossimetasone (OS: DCIT)
- Desoximetasone (OS: BAN, USAN)
- Désoximétasone (OS: DCF)
- Desoxymethasone (OS: BAN)
- Hoe 304 (IS)
- R 2113 (IS)
- Desoximetasone (PH: USP 32)
Brand Names
- Denomix (Desoximetasone and Neomycin)
Combiphar, Indonesia - Dercason
Global Multi Pharmalab, Indonesia - Desicort
Taro, Israel - Desoximetasone
Clay-Park, United States; Fougera, United States; Taro, United States - Dexigen
Ifars, Indonesia - Dexocort
Kimia Farma, Indonesia - Esperson
Jugoremedija, Serbia; Sanofi-Aventis, Brazil; Sanofi-Aventis, Indonesia; Sanofi-Aventis, Philippines; Sanofi-Aventis, Taiwan - Flubason
Sanofi-Aventis, Italy; Sanofi-Aventis S.A., Spain - Ibaril
Bipharma, Netherlands; Sanofi-Aventis, Denmark; Sanofi-Aventis, Finland; Sanofi-Aventis, Norway - Inerson
Interbat, Indonesia - Lerskin
Nufarindo, Indonesia - Topcort
Sanbe, Indonesia - Topicort
Medicis, United States; sanofi-aventis, Canada; Taro, United States - Topicorte
Roussel Laboratories, Ethiopia; Sanofi-Aventis, Netherlands; Sanofi-Aventis, Thailand - Topisolon
Sanofi-Aventis, Germany - Topisolone
Hoechst, Ethiopia
International Drug Name Search
Glossary
BAN | British Approved Name |
DCF | Dénomination Commune Française |
DCIT | Denominazione Comune Italiana |
IS | Inofficial Synonym |
OS | Official Synonym |
PH | Pharmacopoeia Name |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
USAN | United States Adopted Name |
Click for further information on drug naming conventions and International Nonproprietary Names.
No comments:
Post a Comment